16GENOME-WIDE META-ANALYSES REVEAL NOVEL LOCI FOR VERBAL SHORT-TERM MEMORY AND LEARNING AND SHOW GENETIC CORRELATION WITH SCHIZOPHRENIA, ALZHEIMER'S DISEASE, AND TYPE 2 DIABETES

2019 ◽  
Vol 29 ◽  
pp. S1075
Author(s):  
Jari Lahti ◽  
Samuli Tuominen ◽  
Qiong Yang ◽  
Sarah Medland ◽  
Jodie Painter ◽  
...  
Cortex ◽  
2017 ◽  
Vol 88 ◽  
pp. 201-204 ◽  
Author(s):  
Yuying Liang ◽  
Yoni Pertzov ◽  
Jennifer M. Nicholas ◽  
Susie M.D. Henley ◽  
Sebastian Crutch ◽  
...  

2016 ◽  
Vol 127 (6) ◽  
pp. 2423-2435 ◽  
Author(s):  
Robert M. Chapman ◽  
Margaret N. Gardner ◽  
Mark Mapstone ◽  
Rafael Klorman ◽  
Anton P. Porsteinsson ◽  
...  

Brain ◽  
2008 ◽  
Vol 132 (4) ◽  
pp. 1057-1066 ◽  
Author(s):  
M. A. Parra ◽  
S. Abrahams ◽  
K. Fabi ◽  
R. Logie ◽  
S. Luzzi ◽  
...  

2019 ◽  
Vol 40 (7) ◽  
pp. 1441-1452 ◽  
Author(s):  
Oliver Bracko ◽  
Brendah N Njiru ◽  
Madisen Swallow ◽  
Muhammad Ali ◽  
Mohammad Haft-Javaherian ◽  
...  

Alzheimer’s disease is associated with a 20–30% reduction in cerebral blood flow. In the APP/PS1 mouse model of Alzheimer’s disease, inhibiting neutrophil adhesion using an antibody against the neutrophil specific protein Ly6G was recently shown to drive rapid improvements in cerebral blood flow that was accompanied by an improvement in performance on short-term memory tasks. Here, in a longitudinal aging study, we assessed how far into disease development a single injection of anti-Ly6G treatment can acutely improve short-term memory function. We found that APP/PS1 mice as old as 15–16 months had improved performance on the object replacement and Y-maze tests of spatial and working short-term memory, measured at one day after anti-Ly6G treatment. APP/PS1 mice at 17–18 months of age or older did not show acute improvements in cognitive performance, although we did find that capillary stalls were still reduced and cerebral blood flow was still increased by 17% in 21–22-months-old APP/PS1 mice given anti-Ly6G antibody. These data add to the growing body of evidence suggesting that cerebral blood flow reductions are an important contributing factor to the cognitive dysfunction associated with neurodegenerative disease. Thus, interfering with neutrophil adhesion could be a new therapeutic approach for Alzheimer’s disease.


2019 ◽  
Vol 23 ◽  
pp. 101892
Author(s):  
Sophie Kurth ◽  
Mohamed Ali Bahri ◽  
Fabienne Collette ◽  
Christophe Phillips ◽  
Steve Majerus ◽  
...  

NeuroImage ◽  
1996 ◽  
Vol 4 (2) ◽  
pp. 67-77 ◽  
Author(s):  
A.N. Herbster ◽  
T. Nichols ◽  
M.B. Wiseman ◽  
M.A. Mintun ◽  
S.T. DeKosky ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document